Parallel Advisors, LLC Celyad Oncology Sa Call Options Transaction History
Parallel Advisors, LLC
- $4.18 Billion
- Q3 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
About Celyad Oncology SA
- Ticker CYAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,594,000
- Market Cap $11.7M
- Description
- Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cance...